Paper Details

  1. Home
  2. Paper Details

Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.

Author: AndersonGarnet L, BeresfordShirley Aa, ChlebowskiRowan T, GassMargery, KullerLewis H, LaneDorothy S, LavasaniSayeh, MansonJoAnn E, PattersonRuth, PrenticeRoss L, RohanThomas E, RossouwJacques E, ZhaoShanshan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Hormone therapy, particularly with conjugated equine estrogens (CEE), can have complex effects on breast cancer risk. The Women's Health Initiative found that CEE alone may reduce the risk of breast cancer, while CEE combined with medroxyprogesterone acetate (CEE + MPA) increases the risk. This difference may be explained by the effects of hormone therapy on levels of different hormones in the body.
Paper Details　
Original Abstract of the Article :
Paradoxically, a breast cancer risk reduction with conjugated equine estrogens (CEE) and a risk elevation with CEE plus medroxyprogesterone acetate (CEE + MPA) were observed in the Women's Health Initiative (WHI) randomized controlled trials. The effects of hormone therapy on serum sex hormone level...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053241/

データ提供：米国国立医学図書館（NLM）

Hormone Therapy and Breast Cancer Risk: A Complex Interplay

The realm of [hormone therapy] research is riddled with complexities. This study delves into the intricate relationship between [sex hormones], [breast cancer risk], and the impact of hormone therapy on this dynamic interplay. The authors explore the paradoxical findings of the [Women's Health Initiative] randomized controlled trials, where [conjugated equine estrogens (CEE)] showed a risk reduction while [CEE plus medroxyprogesterone acetate (CEE + MPA)] led to an increased risk of breast cancer.

Unraveling the Puzzle: Examining Serum Sex Hormone Levels

By analyzing [serum sex hormone levels] before and after hormone therapy, the study aims to shed light on the mechanisms underlying these divergent findings. The researchers believe that understanding the effects of hormone therapy on [sex hormone levels] and their association with [breast cancer risk] could provide crucial insights into this complex relationship.

Navigating Hormone Therapy: A Balancing Act

This study underscores the importance of a nuanced approach to [hormone therapy]. The findings emphasize the need for individualized consideration of [breast cancer risk] and the potential impact of different hormone therapies on [sex hormone levels]. This knowledge is vital for healthcare professionals in making informed decisions about the benefits and risks of hormone therapy for individual patients.

Dr. Camel's Conclusion

Navigating the complexities of [hormone therapy] is akin to traversing a desert landscape – fraught with hidden dangers and unexpected turns. This study reminds us to approach hormone therapy with a keen eye, considering the intricate interplay of [sex hormones], [breast cancer risk], and the potential effects of different treatments. Understanding these complexities is crucial for making informed decisions and maximizing the benefits while mitigating the risks of hormone therapy.

Date :
  1. Date Completed 2015-02-06
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24670297

DOI: Digital Object Identifier

PMC4053241

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.